Stock Track | Arbutus Biopharma Shares Slide Despite Positive Drug Trial Data

Stock Track

Nov 06, 2024

Shares of Arbutus Biopharma Corp. (ABUS) plummeted by 5.30% on Tuesday, November 6th, as the company reported mixed financial results for the third quarter of 2024.

The biopharmaceutical company reported a loss of $0.10 per share, slightly worse than analysts' expectations of a $0.09 loss. Revenue for the quarter came in at $1.34 million, missing the consensus estimate of $1.86 million by a significant margin.

Despite the disappointing financial performance, Arbutus announced promising results from its Phase 2a clinical trials for imdusiran, a potential treatment for chronic hepatitis B virus (HBV) infection. The company reported positive safety and efficacy data, suggesting that imdusiran could be an effective therapy for HBV patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1115313021"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115313021\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115313021?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115313021","market":"us","top_or_hot":-1,"title":"Stock Track | Arbutus Biopharma Shares Slide Despite Positive Drug Trial Data","media":"Stock Track","content":"<p>Shares of Arbutus Biopharma Corp. (ABUS) plummeted by 5.30% on Tuesday, November 6th, as the company reported mixed financial results for the third quarter of 2024.</p>\n\n<p>The biopharmaceutical company reported a loss of $0.10 per share, slightly worse than analysts' expectations of a $0.09 loss. Revenue for the quarter came in at $1.34 million, missing the consensus estimate of $1.86 million by a significant margin.</p>\n\n<p>Despite the disappointing financial performance, Arbutus announced promising results from its Phase 2a clinical trials for imdusiran, a potential treatment for chronic hepatitis B virus (HBV) infection. The company reported positive safety and efficacy data, suggesting that imdusiran could be an effective therapy for HBV patients.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arbutus Biopharma Shares Slide Despite Positive Drug Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arbutus Biopharma Shares Slide Despite Positive Drug Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-06 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Arbutus Biopharma Corp. (ABUS) plummeted by 5.30% on Tuesday, November 6th, as the company reported mixed financial results for the third quarter of 2024.</p>\n\n<p>The biopharmaceutical company reported a loss of $0.10 per share, slightly worse than analysts' expectations of a $0.09 loss. Revenue for the quarter came in at $1.34 million, missing the consensus estimate of $1.86 million by a significant margin.</p>\n\n<p>Despite the disappointing financial performance, Arbutus announced promising results from its Phase 2a clinical trials for imdusiran, a potential treatment for chronic hepatitis B virus (HBV) infection. The company reported positive safety and efficacy data, suggesting that imdusiran could be an effective therapy for HBV patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABUS","symbol_name":"Arbutus Biopharma Corporation","start_time":0,"source_url":"","article_id":"1115313021","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115313021","pubTimestamp":1730906190,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Arbutus Biopharma Corp.  plummeted by 5.30% on Tuesday, November 6th, as the company reported mixed financial results for the third quarter of 2024.The biopharmaceutical company reported a loss of $0.10 per share, slightly worse than analysts' expectations of a $0.09 loss. Revenue for the quarter came in at $1.34 million, missing the consensus estimate of $1.86 million by a significant margin.Despite the disappointing financial performance, Arbutus announced promising results from its ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABUS":"Arbutus Biopharma Corporation"},"translate_title":"尽管药物试验数据积极，Arbutus Biopharma股价仍下跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABUS":1},"content_text":"Shares of Arbutus Biopharma Corp. (ABUS) plummeted by 5.30% on Tuesday, November 6th, as the company reported mixed financial results for the third quarter of 2024.\nThe biopharmaceutical company reported a loss of $0.10 per share, slightly worse than analysts' expectations of a $0.09 loss. Revenue for the quarter came in at $1.34 million, missing the consensus estimate of $1.86 million by a significant margin.\nDespite the disappointing financial performance, Arbutus announced promising results from its Phase 2a clinical trials for imdusiran, a potential treatment for chronic hepatitis B virus (HBV) infection. The company reported positive safety and efficacy data, suggesting that imdusiran could be an effective therapy for HBV patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}